Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.
- DOI
- 10.1016/j.ejca.2024.115078
- Published
- 2024 Dec
- Container
- European journal of cancer (Oxford, England : 1990)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2024.115078,
title = {Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.},
author = {Azad AA and Fizazi K and Matsubara N and Saad F and De Giorgi U and Joung JY and Fong PCC and Jones RJ and Zschäbitz S and Oldenburg J and Shore ND and Dunshee C and Carles J and Fay AP and Lin X and DeAnnuntis L and Di Santo N and Zielinski MA and Agarwal N},
year = {2024},
journal = {European journal of cancer (Oxford, England : 1990)},
doi = {10.1016/j.ejca.2024.115078},
url = {https://doi.org/10.1016/j.ejca.2024.115078}
}RIS
TY - JOUR TI - Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study. AU - Azad AA AU - Fizazi K AU - Matsubara N AU - Saad F AU - De Giorgi U AU - Joung JY AU - Fong PCC AU - Jones RJ AU - Zschäbitz S AU - Oldenburg J AU - Shore ND AU - Dunshee C AU - Carles J AU - Fay AP AU - Lin X AU - DeAnnuntis L AU - Di Santo N AU - Zielinski MA AU - Agarwal N PY - 2024 JO - European journal of cancer (Oxford, England : 1990) DO - 10.1016/j.ejca.2024.115078 UR - https://doi.org/10.1016/j.ejca.2024.115078 ER -
APA
AA, A., K, F., N, M., F, S., U, D. G., JY, J., PCC, F., RJ, J., S, Z., J, O., ND, S., C, D., J, C., AP, F., X, L., L, D., N, D. S., MA, Z., & N, A. (2024). Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2024.115078
Source records
- pubmed · retrieved 2026-09-27T00:30:48.285Z